Elekta AB Class B
EKTAF
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.91B
Close$
$5.60
7.4% upside
Current Fair Value
7.4% upsideUndervalued by 7.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.91 Billion |
|---|---|
| Enterprise Value | $13.40 Billion |
| Dividend Yield | $0.26 (4.90%) |
| Earnings per Share | $-1.38 |
| Beta | 0.96 |
| Outstanding Shares | 382,083,120 |
Return
| Return on Equity | -7.48% |
|---|---|
| Return on Assets | -2.12% |
| Return on Invested Capital | 5.69% |
Valuation & Multiples
| P/E Ratio | -51.94 |
|---|---|
| PEG | -35.62 |
| Price to Sales | 0.12 |
| Price to Book Ratio | 0.27 |
| Enterprise Value to Revenue | 0.81 |
| Enterprise Value to EBIT | 19.24 |
| Enterprise Value to Net Income | -24 |
| Total Debt to Enterprise | 1.03 |
| Debt to Equity | 1.83 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
$0.05
Average shareholder expectationRevenue Estimate
$380.56 M
Average shareholder expectationNext Earnings Call
Expected Date
November 25, 2026
EPS Estimate
$0.09
Average shareholder expectationRevenue Estimate
$427.31 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Elekta AB
CEO: Gustaf Salford Elekta AB is a medical technology company. It engages in the provision of clinical solutions for the treatment of cancers and brain disorders. The firm's products and solutions include radiotherapy, stereotactic radiosurgery, oncology in...